Initial characteristics of ITP patients at day 0 who were eventually converted to secondary ITP or non-IT during follow-up
| Characteristic . | Total . | Subgroup . | |||||
|---|---|---|---|---|---|---|---|
| Infection . | Autoimmunity . | Aplastic anemia . | Malignancy . | Immunodeficiency . | Drug-induced . | ||
| Total patients (%) | 113 (100) | 53 (47) | 42 (37) | 6 (5) | 7 (6) | 4 (4) | 1 (1) |
| Female | 63 (56) | 26 (49) | 29 (69) | 1 (17) | 5 (71) | 2 (50) | |
| Male | 50 (47) | 27 (51) | 13 (31) | 5 (83) | 2 (29) | 2 (50) | 1 |
| Age, median (IQR), y | 6.4 (2.8;12.4) | 3.22* (1.2; 6.7) | 12.4* (7.6; 13.7) | 5.8 (3.6; 10) | 3 (1.7; 10.7) | 11.7 (7.2; 14.3) | 13.7 |
| Family history of thrombocytopenia (%) | 4 (4) | 0(0)† | 3 (7)† | 0 | 0 | 1 (25) | 0 |
| Comorbidities (%) | 26 (23) | 8 (15)† | 13 (31)† | 2 (33) | 1 (14) | 2 (50) | 0 |
| Autoimmune | 2 | — | 2 | — | — | — | |
| Thyroid | 2 | 1 | 1 | — | — | ||
| Cardiovascular | 5 | — | 4 | — | — | 1 | |
| Infection | 12 | 6 | 4 | 1 | — | 1 | |
| Other | 5 | 1 | 2 | 1 | 1 | — | |
| Platelet count, median (IQR), ×109/L | 14 (7; 29) | 12 (6; 28) | 13 (7; 24) | 52 (21;72) | 37 (28; 40) | 21 (15; 31) | 1 |
| No. of patients with platelet count <20 × 109/L, initial (%) | 69 (61) | 35 (66) | 28 (67) | 2 (33) | 1 (14) | 2 (50) | 1 |
| No bleeding, initial (%) | 20 (18) | 6 (11)† | 11 (26)† | 2 (33) | 0 (0) | 1 (25) | 0 |
| Platelet-enhancing treatment, initial (%) | 73 (65) | 37 (70) | 30 (71) | 1 (17) | 2 (29) | 2 (50) | 1 |
| First-line treatment‡ | 71 | ||||||
| Second-line treatment§ | 2 | ||||||
| Characteristic . | Total . | Subgroup . | |||||
|---|---|---|---|---|---|---|---|
| Infection . | Autoimmunity . | Aplastic anemia . | Malignancy . | Immunodeficiency . | Drug-induced . | ||
| Total patients (%) | 113 (100) | 53 (47) | 42 (37) | 6 (5) | 7 (6) | 4 (4) | 1 (1) |
| Female | 63 (56) | 26 (49) | 29 (69) | 1 (17) | 5 (71) | 2 (50) | |
| Male | 50 (47) | 27 (51) | 13 (31) | 5 (83) | 2 (29) | 2 (50) | 1 |
| Age, median (IQR), y | 6.4 (2.8;12.4) | 3.22* (1.2; 6.7) | 12.4* (7.6; 13.7) | 5.8 (3.6; 10) | 3 (1.7; 10.7) | 11.7 (7.2; 14.3) | 13.7 |
| Family history of thrombocytopenia (%) | 4 (4) | 0(0)† | 3 (7)† | 0 | 0 | 1 (25) | 0 |
| Comorbidities (%) | 26 (23) | 8 (15)† | 13 (31)† | 2 (33) | 1 (14) | 2 (50) | 0 |
| Autoimmune | 2 | — | 2 | — | — | — | |
| Thyroid | 2 | 1 | 1 | — | — | ||
| Cardiovascular | 5 | — | 4 | — | — | 1 | |
| Infection | 12 | 6 | 4 | 1 | — | 1 | |
| Other | 5 | 1 | 2 | 1 | 1 | — | |
| Platelet count, median (IQR), ×109/L | 14 (7; 29) | 12 (6; 28) | 13 (7; 24) | 52 (21;72) | 37 (28; 40) | 21 (15; 31) | 1 |
| No. of patients with platelet count <20 × 109/L, initial (%) | 69 (61) | 35 (66) | 28 (67) | 2 (33) | 1 (14) | 2 (50) | 1 |
| No bleeding, initial (%) | 20 (18) | 6 (11)† | 11 (26)† | 2 (33) | 0 (0) | 1 (25) | 0 |
| Platelet-enhancing treatment, initial (%) | 73 (65) | 37 (70) | 30 (71) | 1 (17) | 2 (29) | 2 (50) | 1 |
| First-line treatment‡ | 71 | ||||||
| Second-line treatment§ | 2 | ||||||
% refers to the total number of patients in the subgroups.
Between the subgroups infection-associated and autoimmune-associated ITP, P < 0.001.
Between the subgroups infection-associated and autoimmune-associated ITP, P = nonsignificant.
First-line treatment: corticosteroids, anti-D immunoglobulin, and IVIG.
Second-line treatment: drugs other than corticosteroids, anti-D immunoglobulin, or IVIG.